arterial access News
-
Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients
Nationally there is a trend moving towards radial artery access versus femoral artery access for endovascular procedures and Q’Apel Medical is leading the way. Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today the launch of the Armadillo Radial Access ...
-
First-in-Human Trial Evaluates Safety and Efficacy of Rex Medical`s Large Bore Closer System
November 7, 2018 — At VIVA 2018, the Vascular Interventional Advances annual conference held November 5–8 in Las Vegas, Nevada, Micah Watts, MD, presented findings from the first-in-human clinical trial of the Large Bore Closer vascular sealing system (Rex Medical). The trial evaluated 23 patients at a single site and assessed the safety and effectiveness of the Large Bore Closer ...
-
Biomodex Teams Up with Physicians at Three of the World’s Top Medical Centers to Develop a Cutting-Edge Training Solution for Treatment of Ischemic Stroke
BIOMODEX, a pioneering digital health company that offers a unique and enhanced 3D printed solution for physician training, announced today the company has partnered with two of the top medical centers in France and a world-class health system in the United States to develop EVIAS Plus - an innovative training solution for treatment of ischemic stroke. Ischemic stroke accounts for about 87 ...
By BIOMODEX
-
Silicon Valley-Based Silk Road Medical Announces Expansion to MSP Region
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, recently announced the opening of a new office in Plymouth, Minnesota, to accommodate growing demand for TransCarotid Artery Revascularization (TCAR) and to access the local talent pool of aspiring and experienced med tech professionals. “We continue to invest in our ...
-
Xeltis lands €15 million European financing from EIB
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available under the European Guarantee Fund (EGF), an EIB Group initiative in partnership with EU Member ...
By XELTIS BV
-
Silk Road Medical Announces FDA Approval of Expanded Indications for the ENROUTE Transcarotid Stent System
Silk Road Medical, Inc.?(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with ...
-
First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for ...
-
JenaValve Technology Receives CE Mark for its Trilogy TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its TrilogyTM Heart Valve System for the treatment of both aortic regurgitation (AR), also known as aortic ...
-
Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open. The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you